Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 November 2011Website:
http://www.fortressbiotech.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:30:26 GMTDividend
Analysts recommendations
Institutional Ownership
FBIO Latest News
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 11:30 a.m. ET. The Company will also attend one-on-one meetings during the conference.
Fortress Biotech (FBIO) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.18 per share a year ago.
What type of business is Fortress Biotech?
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
What sector is Fortress Biotech in?
Fortress Biotech is in the Healthcare sector
What industry is Fortress Biotech in?
Fortress Biotech is in the Biotechnology industry
What country is Fortress Biotech from?
Fortress Biotech is headquartered in United States
When did Fortress Biotech go public?
Fortress Biotech initial public offering (IPO) was on 17 November 2011
What is Fortress Biotech website?
https://www.fortressbiotech.com
Is Fortress Biotech in the S&P 500?
No, Fortress Biotech is not included in the S&P 500 index
Is Fortress Biotech in the NASDAQ 100?
No, Fortress Biotech is not included in the NASDAQ 100 index
Is Fortress Biotech in the Dow Jones?
No, Fortress Biotech is not included in the Dow Jones index
When does Fortress Biotech report earnings?
The next expected earnings date for Fortress Biotech is 07 November 2024